SAB Biotherapeutics (NASDAQ:SABS) Rating Reiterated by Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a research report issued on Tuesday, Benzinga reports. They currently have a $25.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 443.48% from the company’s previous close.

Separately, HC Wainwright lowered their price target on shares of SAB Biotherapeutics from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd.

SAB Biotherapeutics Stock Down 5.7 %

SABS stock opened at $4.60 on Tuesday. SAB Biotherapeutics has a 12 month low of $4.00 and a 12 month high of $14.50. The firm’s fifty day simple moving average is $4.94 and its 200-day simple moving average is $3.12. The company has a quick ratio of 5.45, a current ratio of 5.45 and a debt-to-equity ratio of 0.06.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of SAB Biotherapeutics by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 976,938 shares of the company’s stock valued at $615,000 after purchasing an additional 14,200 shares in the last quarter. State Street Corp increased its holdings in SAB Biotherapeutics by 244.2% in the first quarter. State Street Corp now owns 42,341 shares of the company’s stock valued at $159,000 after buying an additional 30,041 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of SAB Biotherapeutics in the third quarter worth about $28,000. Renaissance Technologies LLC purchased a new stake in shares of SAB Biotherapeutics during the 2nd quarter worth about $45,000. Finally, Millennium Management LLC acquired a new stake in shares of SAB Biotherapeutics during the 2nd quarter valued at about $93,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.